Patton Fund Management Inc. Grows Position in Gilead Sciences, Inc. $GILD

Patton Fund Management Inc. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2,693.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 59,605 shares of the biopharmaceutical company’s stock after acquiring an additional 57,471 shares during the period. Patton Fund Management Inc.’s holdings in Gilead Sciences were worth $7,316,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Atwater Malick LLC bought a new position in shares of Gilead Sciences during the 4th quarter valued at about $255,000. Intelligence Driven Advisers LLC increased its position in shares of Gilead Sciences by 19.7% during the 4th quarter. Intelligence Driven Advisers LLC now owns 2,897 shares of the biopharmaceutical company’s stock valued at $356,000 after purchasing an additional 476 shares during the last quarter. Webster Bank N. A. increased its position in shares of Gilead Sciences by 11.3% during the 4th quarter. Webster Bank N. A. now owns 875 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 89 shares during the last quarter. Transcend Capital Advisors LLC increased its position in shares of Gilead Sciences by 4.9% during the 4th quarter. Transcend Capital Advisors LLC now owns 6,505 shares of the biopharmaceutical company’s stock valued at $798,000 after purchasing an additional 301 shares during the last quarter. Finally, Tectonic Advisors LLC increased its position in shares of Gilead Sciences by 3.9% during the 4th quarter. Tectonic Advisors LLC now owns 97,332 shares of the biopharmaceutical company’s stock valued at $11,947,000 after purchasing an additional 3,650 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the sale, the chief executive officer directly owned 642,308 shares of the company’s stock, valued at $92,999,775.32. The trade was a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director directly owned 8,920 shares in the company, valued at $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 299,280 shares of company stock valued at $42,820,550. Insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $139.03 on Tuesday. The stock has a 50-day simple moving average of $145.05 and a two-hundred day simple moving average of $130.79. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The firm has a market capitalization of $172.57 billion, a PE ratio of 20.54, a P/E/G ratio of 1.85 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the previous year, the company posted $1.90 earnings per share. Gilead Sciences’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were paid a dividend of $0.82 per share. The ex-dividend date of this dividend was Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.4%. Gilead Sciences’s payout ratio is presently 48.45%.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Leerink Partners increased their price objective on Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a research report on Wednesday, February 11th. Daiwa Securities Group lifted their price objective on Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Wells Fargo & Company lifted their target price on Gilead Sciences from $150.00 to $165.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. UBS Group lifted their price objective on Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, BMO Capital Markets lifted their price objective on Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, January 26th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $156.77.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.